TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT05755113: A Clinical Study to Investigate the Efficacy of Intratumoral Tigilanol Tiglate in Soft Tissue Sarcoma

Sponsor: QBiotics Group Limited · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 40 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$14,784,000

Rescue Site Savings

+$9,748,200

Unlock Full NCT05755113 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05755113 Rescue Dossier →